This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Buying Tenet (THC) Pre-Q2 Earnings: A Prescription for Profits?
by Kaibalya Pravo Dey
Tenet Healthcare's (THC) second-quarter earnings are likely to have benefited from higher admissions, average length of stay and patient days.
THCPositive Net Change CYHNo Net Change HCAPositive Net Change
earnings-preview hospitals medical
GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio
by Zacks Equity Research
GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.
UHSNegative Net Change HOLXPositive Net Change ELVNegative Net Change GEHCNegative Net Change
medical medical-devices
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
by Zacks Equity Research
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
MRNANegative Net Change CORNegative Net Change HCAPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
4 Healthcare Stocks Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.
UHSNegative Net Change CINegative Net Change THCPositive Net Change HCAPositive Net Change
earnings medical
Globus Medical (GMED) Global Sales, Innovation Aid Growth
by Zacks Equity Research
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
HAEPositive Net Change GMEDPositive Net Change VCYTNegative Net Change HIMSNegative Net Change
medical
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
by Zacks Equity Research
Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication
DGXNegative Net Change UHSNegative Net Change HAEPositive Net Change PDCONegative Net Change
medical medical-devices
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
by Zacks Equity Research
Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.
BIIBPositive Net Change NBIXPositive Net Change SAGEPositive Net Change ACRSPositive Net Change
medical
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
ISRGPositive Net Change HOLXPositive Net Change MASINegative Net Change GMEDPositive Net Change
earnings medical medical-devices
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
by Ekta Bagri
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
VRTXPositive Net Change PRMENegative Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
by Zacks Equity Research
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
AZNPositive Net Change NVSNegative Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs medical pharmaceuticals
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechs earnings-preview medical pharmaceuticals
Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
ALGNPositive Net Change HCAPositive Net Change HIMSNegative Net Change HITIPositive Net Change
earnings medical
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
TEVAPositive Net Change ANIPPositive Net Change ADPTNegative Net Change RAPTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
by Zacks Equity Research
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
HOLXPositive Net Change HCAPositive Net Change PENNegative Net Change HIMSNegative Net Change
earnings medical medical-devices
Implied Volatility Surging for Integra (IART) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Integra (IART) stock based on the movements in the options market lately.
IARTPositive Net Change
medical medical-devices
5 Non-Tech Nasdaq Stocks to Buy Amid Index's Recent Bloodbath
by Nalak Das
We have narrowed our search to five Nasdaq Composite-listed non-tech stocks. These are: COST, ISRG, IBKR, TXRH, FSLR.
FSLRPositive Net Change ISRGPositive Net Change IBKRPositive Net Change TXRHPositive Net Change COSTNegative Net Change
alt-energy finance medical restaurants retail
Top Stocks to Buy for Growth as Earnings Approach
by Shaun Pruitt
Investors will want to pay attention to several top-rated Zacks stocks that are set to report their quarterly results on Monday, July 22.
LOGINegative Net Change RLINegative Net Change MEDPNegative Net Change
computers earnings finance insurance investing medical tech-stocks
Markets Book Profits; Netflix, Intuitive Beat Estimates in Q2
by Mark Vickery
Year-to-date, the Nasdaq is still +20%, the S&P +16%, the Russell +9% and the Dow +7.5%.
SLBPositive Net Change NFLXNegative Net Change AXPNegative Net Change ISRGPositive Net Change TRVNegative Net Change
earnings fang medical medical-devices
Will High Medical Care Costs Hurt Molina's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina's (MOH) second-quarter performance is likely to have been affected by high medical care costs, partly offset by rising membership in all three businesses.
UHSNegative Net Change MOHPositive Net Change CINegative Net Change CORNegative Net Change
earnings medical
Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.
UHSNegative Net Change CINegative Net Change CORNegative Net Change HCAPositive Net Change
medical
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
BSXPositive Net Change ISRGPositive Net Change HAEPositive Net Change MASINegative Net Change
medical medical-devices
Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
BSXPositive Net Change ISRGPositive Net Change HAEPositive Net Change GMEDPositive Net Change
medical medical-devices
Q2 Earnings Season Scorecard, Economic Outlook and Analyst Reports for NVIDIA, Meta & Others
by Sheraz Mian
Today's Research Daily features the Q2 earnings season scorecard and fresh research reports on NVIDIA (NVDA), Meta (META), Amgen and others.
GEPositive Net Change UNHPositive Net Change AMGNPositive Net Change BHPNegative Net Change NVDANegative Net Change GLXZPositive Net Change METAPositive Net Change
computers consumer-discretionary medical semiconductor
Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.
UHSNegative Net Change HCAPositive Net Change PENNegative Net Change HIMSNegative Net Change
earnings medical
Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software
by Zacks Equity Research
Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.
UHSNegative Net Change HOLXPositive Net Change HYPRNegative Net Change ELVNegative Net Change
medical medical-devices